# Study of Combined VisioCyt Test and FGFR3 Mutations on a Urinary Sample to Diagnose Bladder Tumors

> **NCT05151341** · NA · COMPLETED · sponsor: **Institut de Cancérologie de Lorraine** · enrollment: 190 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Urine collection (150ml)
- **OTHER:** Blood sample (20 ml)

## Key facts

- **NCT ID:** NCT05151341
- **Lead sponsor:** Institut de Cancérologie de Lorraine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-13
- **Primary completion:** 2024-12-12
- **Final completion:** 2025-06-12
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2025-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05151341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05151341, "Study of Combined VisioCyt Test and FGFR3 Mutations on a Urinary Sample to Diagnose Bladder Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05151341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*